In my view, the next big announcement shall be a big pharma partner for COVID-19. The last 4C put the discussions ongoing for at least a month. During the last conf call, the CFO refused to get drawn into a discussion or answer the analyst question on funds allocated for manufacturing in next quarters. Maybe the last fresh equity funds raise put the company in a better negotiation position, but won’t actually be needed for manufacturing if there is a big pharmaceutical partnership....
Here is an excerpt from MESOBLAST’s last 4C: “Mesoblast is in active discussions with US and other government authorities as well as potential pharmaceutical partners with respect to its plans for ramp-up of commercial manufacturing for remestemcel-L in COVID-19 ARDS.”
http://investorsmedia.mesoblast.com/static-files/04851ade-aca5-492c-9784-45ae8c772f04
Ann: Remestemcel-L Improves Outcomes in Inflammatory Lung Disease, page-144
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
-0.025(2.38%) |
Mkt cap ! $1.164B | |||
| Open | High | Low | Value | Volume |
| $1.06 | $1.06 | $1.02 | $2.869M | 2.782M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 169701 | $1.03 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 89163 | 16 |
View Market Depth
| Last trade - 11.30am 16/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.03 |
Change
-0.025 ( 2.47 %) |
||||
| Open | High | Low | Volume | ||
| $1.06 | $1.06 | $1.02 | 340562 | ||
| Last updated 11.47am 16/05/2024 ? | |||||
| MSB (ASX) Chart |